Metformin IN Asthma for Overweight and Obese Individuals (MINA)
This is a randomized clinical trial of metformin among overweight or obese adults with not well-controlled asthma despite maintenance inhaler therapy.
- EligibilityCriteria: Inclusion Criteria:  Physician-diagnosed asthma on maintenance therapy Not well-controlled asthma (ACT score <20, or at least one asthma exacerbation requiring corticosteroids in the prior 12 months) Overweight or obesity: Body mass index ≥25kg/m2 Adult: Age ≥18  Exclusion Criteria:  Currently pregnant, expect to become pregnant in the next 6 months or are currently breastfeeding Major cardiovascular disease: heart failure, heart attack or stroke within the last 6 months Other chronic lung disease, inclusive of chronic obstructive pulmonary disease, bronchiectasis, interstitial lung disease, pulmonary fibrosis Active smoking or former smoker with ≥20 pack-year smoking history Chronic kidney disease: estimated glomerular filtration rate ≤60 mL/min/1.73 m2 Heavy alcohol use: in a typical week, 8 or more drinks for a woman or 15 or more drinks for a man Liver disease: elevation in aspartate aminotransferase (AST) or alanine aminotransferase (ALT) > 2x the upper limit of normal or prior diagnosis of liver disease Anemia: hemoglobin < 13 g/dl in males and hemoglobin < 11 g/dl in females Taking Glucagon Like Peptide 1(GLP-1) medications for weight loss Diabetes (Hemoglobin A1C ≥ 6.5% or taking metformin or other medications used to treat diabetes) Participation in any other clinical trial (observational studies are permitted) - HealthyVolunteers: No - Gender: All - MinimumAge: 18 Years - StdAgeList: Adult, Older Adult